Lineage Cell Therapeutics, Inc. Inventory Write-down
Lineage Cell Therapeutics, Inc. (LCTX) reported Inventory Write-down of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2014-03-17
- Lineage Cell Therapeutics, Inc. inventory write-down for the quarter ending 2012-12-31 was $0.00.
- Lineage Cell Therapeutics, Inc. inventory write-down for the quarter ending 2012-09-30 was $0.00.
- Lineage Cell Therapeutics, Inc. inventory write-down for the quarter ending 2012-06-30 was $0.00.
- Lineage Cell Therapeutics, Inc. inventory write-down for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- Lineage Cell Therapeutics, Inc. inventory write-down for fiscal 2013 was $0.00.
- Lineage Cell Therapeutics, Inc. inventory write-down for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Lineage Cell Therapeutics, Inc. inventory write-down for fiscal 2011 was $1.51K, a 62.33% decline from fiscal 2010.
- Lineage Cell Therapeutics, Inc. inventory write-down for fiscal 2010 was $4.01K.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-17 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $0.00 derived: sum of 2 quarters · filed 2014-03-17 | $0.00 derived: sum of 3 quarters · filed 2014-03-17 | $0.00 10-K · filed 2014-03-17 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $0.00 derived: sum of 2 quarters · filed 2012-11-09 | $0.00 10-Q · filed 2012-11-09 | $0.00 derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $0.00 10-Q · filed 2012-08-09 | $0.00 derived: sum of 3 quarters · filed 2014-03-17 | $0.00 derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $0.00 derived: sum of 2 quarters · filed 2014-03-17 | $0.00 derived: sum of 3 quarters · filed 2014-03-17 | -$2.50K derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $0.00 derived: sum of 2 quarters · filed 2014-03-17 | -$2.50K derived: sum of 3 quarters · filed 2014-03-17 | $1.51K 10-K · filed 2014-03-17 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$2.50K derived: sum of 2 quarters · filed 2012-11-09 | $1.51K 10-Q · filed 2012-11-09 | $5.52K derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | -$2.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $1.51K 10-Q · filed 2012-08-09 | $5.52K derived: sum of 3 quarters · filed 2013-03-18 | $5.52K derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $4.01K 10-Q · filed 2012-05-10 | $8.02K derived: sum of 2 quarters · filed 2013-03-18 | $8.02K derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | $4.01K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $4.01K derived: sum of 2 quarters · filed 2013-03-18 | $4.01K 10-K · filed 2013-03-18 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $0.00 10-Q · filed 2011-11-08 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |